AWWA ACE65188 PDF

AWWA ACE65188 PDF

Name:
AWWA ACE65188 PDF

Published Date:
06/01/2007

Status:
Active

Description:

Piloting and Life-Cycle Analysis as Useful Tools for the Selection of a New Treatment Process for the Town of Smiths Falls New WTP

Publisher:
American Water Works Association

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Russian version):
200 business days

SKU:

Choose Document Language:
Need Help?
The Town of Smiths Falls' (Ontario, Canada) existing water treatment plant (WTP) was built in the late 1800's, and although there have been many upgrades throughout the past century, the plant has had difficulty treating water to the level expected by its customers. Drinking water treatment at the existing facility consists of coagulation, flocculation, sedimentation, granular activated carbon capped dual media filters, and gaseous chlorination. There is currently no residue management at the plant, and backwash water from the filters and sludge from the sedimentation tanks are sent directly to the Rideau River without treatment. An environmental study performed in 2003 recommended that the existing water treatment plant be replaced with a new facility to help meet regulatory guidelines and increase the aesthetic level of treatment. Although a potential treatment train was identified at that time, it was not finalized. When the Town of Smiths Falls commissioned the services of R.V. Anderson Associates Limited (RVA) for the design of the new WTP, it was determined that dual media filtration would be used as it was successful at the existing plant, and ultraviolet (UV) disinfection would be used to help meet future regulations. However, there was not enough information available to definitively determine the remaining components of the treatment train. The Town of Smiths Falls identified that the new water treatment plant design would focus on the following primary objectives: meet current and potential future drinking water regulations; effectively remove taste and odor causing compounds; effectively remove color; provide for ease of operation and maintenance; and, offer multi-barrier protection. The Town, based on the recommendation of RVA in conjunction with Andrews, Hofmann and Associates, decided to conduct a pilot study to determine which treatment(s) would effectively remove the aesthetic parameters while offering safe drinking water. It is unlikely that one treatment process could effectively control both color and T&O. Therefore, it was determined that some kind of pretreatment would be necessary to control color and that another process would be necessary to control T&O. The pretreatment processes that were considered for further investigation for color removal include pre-oxidation, conventional treatment (coagulation, sedimentation, filtration), and the proprietary high rate clarification processes Actiflo and AquaDAF. Processes that were considered for further investigation for T&O removal include: advanced oxidation (AO) with UV and hydrogen peroxide; granular activated carbon (GAC); and, ozone. The primary objective of the pilot study was to identify which processes would be capable of consistently meeting the treatment and operation goals of the Town (including all three significant events). The ineffective processes could be ruled out, and the successful processes could then be compared using detailed information collected during the pilot study. Includes tables.
Edition : Vol. - No.
Number of Pages : 8
Published : 06/01/2007

History


Related products

AWWA ACE65125
Published Date: 06/01/2007
Disinfection of Water with Ultraviolet Light and Ultrasound
$7.2
AWWA ACE65377
Published Date: 06/01/2007
Nanotechnology, Nanoparticles and Drinking Water: Threats and Opportunities
$7.2
AWWA ACE65145
Published Date: 06/01/2007
Systems Modeling for Development and Analysis of Alternatives for Sustainable Groundwater Management
$7.2
AWWA ACE65494
Published Date: 06/01/2007
When It Rains, Grab a Bucket
$7.2

Best-Selling Products

Alzheimer's Disease Report
Published Date: 12/01/2018
$2398.5
Cystic Fibrosis Disease Report
Published Date: 04/01/2019
$2398.5
Multiple Sclerosis Disease Report
Published Date: 12/01/2018
$2398.5
Non-Alcoholic Steatohepatitis Disease Report
Published Date: 12/01/2018
$2398.5
Non-Hodgkin's Lymphoma Disease Report
Published Date: 12/01/2018
$2398.5